Clinical Trial Update: TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria [NA]

View source ↗

Summary

This entry reports a clinical trial (TITAN-HCC) evaluating QL1706 with transarterial chemoembolization (TACE) as neoadjuvant and adjuvant therapy in resectable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• QL1706

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma (HCC) | NA | Status: NOT_YET_RECRUITING